To start your customized experience click the start button
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Angelica Welch
Vaccines are currently being tested in their potential to improve immunotherapy responses for patients with renal cell carcinoma.
Danielle Bucco
Elizabeth Plimack, M.D., discusses an update on the CheckMate-025 trial, comparing Opdivo to Afinitor in patients with metastatic renal cell carcinoma.
Danielle Bucco
David F. McDermott, M.D., is optimistic about combination regimens shaping the treatment landscape for renal cell carcinoma. 
Gina Columbus
After the approvals of agents in the second-line setting, researchers are now turning to improving the frontline treatment of kidney cancer.
Gina Columbus
Will the newly approved kidney cancer treatments eventually end up in the frontline setting? Expert  Chung-Han (Joe) Lee, M.D., weighs in.
Don Vaughan
Obesity can negatively affect cancer treatment outcomes, trigger disease recurrence and shorten longevity. Organized weight loss programs and exercise can help patients protect themselves.
Laura Panjwani
Immunotherapy combinations are on the horizon for the treatment of renal cell carcinoma, Robert J. Motzer, M.D., says. 
Christian M. Capitini, M.D.
Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.
A panel of experts recently discussed the evolving field of immunotherapy for solid tumor types.
Brielle Urciuoli
TKIs will continue to shape the landscape of kidney cancer treatment, Robert A. Figlin, M.D., F.A.C.P., says.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable